Effect of a Single High-Dose Vitamin D-3 on the Le... - BV FAPESP
Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Effect of a Single High-Dose Vitamin D-3 on the Length of Hospital Stay of Severely 25-Hydroxyvitamin D-Deficient Patients with COVID-19

Texto completo
Autor(es):
Murai, Igor H. [1] ; Fernandes, Alan L. [1] ; Antonangelo, Leila [2] ; Gualano, Bruno [1] ; Rodrigues Pereira, Rosa Maria [1]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Fac Med FMUSP, Div Reumatol, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Div Patol Clin, Sao Paulo, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: Clinics; v. 76, 2021.
Citações Web of Science: 1
Resumo

OBJECTIVES: In this ancillary analysis of a multicenter, double-blinded, randomized, placebo-controlled trial, we investigated the effect of a single high dose of vitamin D-3 on the length of hospital stay of patients with severe 25-hydroxyvitamin D deficiency and COVID-19. METHODS: The primary outcome was length of hospital stay, defined as the total number of days that patients remained hospitalized from the date of randomization until the date of hospital discharge. Secondary outcomes included serum levels of 25-hydroxyvitamin D, mortality during hospitalization, number of patients admitted to the intensive care unit, and number of patients who required mechanical ventilation. RESULTS: Thirty-two patients were included in the study. The mean (SD) age was 58.5 (15.6) years, body mass index was 30.8 (8.6) kg/m(2), and 25-hydroxyvitamin D level was 7.8 (1.6) ng/mL. No significant difference was observed in the median interquartile range of length of hospital stay between the vitamin D-3 group (6.0 {[}4.0- 18.0] days) versus placebo (9.5 {[}6.3-15.5] days) (log-rank p=0.74; hazard ratio, 1.13 {[}95% confidence interval (CI), 0.53-2.40]; p=0.76). Vitamin D-3 significantly increased serum 25-hydroxyvitamin D levels in the vitamin D-3 group compared with that in the placebo group (between-group difference, 23.9 ng/mL {[}95% CI, 17.7-30.1]; p<0.001). CONCLUSIONS: A dose of 200.000 IU of vitamin D-3 did not significantly reduce the length of hospital stay of patients with severe 25-hydroxyvitamin D deficiency and COVID-19. (AU)

Processo FAPESP: 20/11102-2 - Suplementação com vitamina D em pacientes com COVID-19: ensaio clínico, randomizado, duplo-cego e controlado por placebo
Beneficiário:Alan Lins Fernandes
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 19/24782-4 - Comparação dos mecanismos de perda óssea em pacientes submetidos à derivação gástrica em Y de Roux ou gastrectomia vertical
Beneficiário:Igor Hisashi Murai
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 20/05752-4 - Suplementação com vitamina D em pacientes com COVID-19: ensaio clínico, randomizado, duplo-cego e controlado por placebo
Beneficiário:Rosa Maria Rodrigues Pereira
Modalidade de apoio: Auxílio à Pesquisa - Regular